142 related articles for article (PubMed ID: 15090742)
1. XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
Brooks TD; Wang SW; Brünner N; Charlton PA
Anticancer Drugs; 2004 Jan; 15(1):37-44. PubMed ID: 15090742
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.
Brooks TD; Slomp J; Quax PH; De Bart AC; Spencer MT; Verheijen JH; Charlton PA
Clin Exp Metastasis; 2000; 18(6):445-53. PubMed ID: 11592301
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Whitley BR; Beaulieu LM; Carter JC; Church FC
Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.
Fortenberry YM; Brandal SM; Carpentier G; Hemani M; Pathak AP
PLoS One; 2016; 11(10):e0164288. PubMed ID: 27755560
[TBL] [Abstract][Full Text] [Related]
5. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
6. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells.
Liu G; Shuman MA; Cohen RL
Int J Cancer; 1995 Feb; 60(4):501-6. PubMed ID: 7829264
[TBL] [Abstract][Full Text] [Related]
8. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Lobov S; Ranson M
Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species.
Park MJ; Lee JY; Kwak HJ; Park CM; Lee HC; Woo SH; Jin HO; Han CJ; An S; Lee SH; Chung HY; Park IC; Hong SI; Rhee CH
J Cell Biochem; 2005 Aug; 95(5):955-69. PubMed ID: 15962302
[TBL] [Abstract][Full Text] [Related]
10. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
[TBL] [Abstract][Full Text] [Related]
13. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis.
Pepper MS; Montesano R; Mandriota SJ; Orci L; Vassalli JD
Enzyme Protein; 1996; 49(1-3):138-62. PubMed ID: 8797003
[TBL] [Abstract][Full Text] [Related]
15. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
16. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
17. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.
Swiercz R; Keck RW; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2001; 8(3):463-70. PubMed ID: 11295064
[TBL] [Abstract][Full Text] [Related]
18. Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Whitley BR; Palmieri D; Twerdi CD; Church FC
Exp Cell Res; 2004 Jun; 296(2):151-62. PubMed ID: 15149846
[TBL] [Abstract][Full Text] [Related]
19. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
[TBL] [Abstract][Full Text] [Related]
20. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.
Placencio VR; Ichimura A; Miyata T; DeClerck YA
PLoS One; 2015; 10(7):e0133786. PubMed ID: 26207899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]